Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $285,150.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 5,000 shares of Akero Therapeutics stock in a transaction on Monday, January 27th. The stock was sold at an average price of $57.03, for a total transaction of $285,150.00. Following the transaction, the vice president now owns 33,492 shares in the company, valued at approximately $1,910,048.76. This trade represents a 12.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Patrick Lamy also recently made the following trade(s):

• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $29.13, for a total transaction of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total transaction of $28,480.75.

Akero Therapeutics Trading Down 2.3 %

NASDAQ:AKRO opened at $54.08 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The firm has a 50-day moving average of $30.26 and a 200-day moving average of $28.88. The company has a market cap of $3.77 billion, a PE ratio of -14.42 and a beta of -0.19. Akero Therapeutics, Inc. has a one year low of $15.32 and a one year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). As a group, equities research analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after purchasing an additional 446 shares in the last quarter. Eastern Bank bought a new stake in Akero Therapeutics in the 3rd quarter worth about $100,000. Summit Financial Wealth Advisors LLC bought a new stake in Akero Therapeutics in the 3rd quarter worth about $205,000. Victory Capital Management Inc. bought a new stake in Akero Therapeutics in the 3rd quarter worth about $211,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Akero Therapeutics in the 3rd quarter worth about $265,000.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $35.00 to $63.00 in a report on Thursday. Citigroup lifted their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday. Morgan Stanley lifted their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, UBS Group lifted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $75.86.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.